ArticleOncology letters2020
Downregulation of miR-19a inhibits the proliferation and promotes the apoptosis of osteosarcoma cells by regulating the JAK2/STAT3 pathway.
Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Crosstalk between miRNAs and oxidative stress: implications for cancer pathogenesis and therapy.Functional & integrative genomics · 2025Review
- CircRNA-CIRH1A Promotes the Development of Osteosarcoma by Regulating PI3K/AKT and JAK2/STAT3 Signaling Pathways.Molecular biotechnology · 2024Article
- TMJ-105, an extract ofHeliyon · 2024Article
- Decoding the interaction between miR-19a and CBX7 focusing on the implications for tumor suppression in cancer therapy.Medical oncology (Northwood, London, England) · 2023Review
- LncRNA KIAA0087 suppresses the progression of osteosarcoma by mediating the SOCS1/JAK2/STAT3 signaling pathway.Experimental & molecular medicine · 2023Article
- Article
- Non-coding RNAs as potential biomarkers in osteosarcoma.Frontiers in genetics · 2022Review
- Circulating microRNA Panel as a Potential Novel Biomarker for Oral Squamous Cell Carcinoma Diagnosis.Cancers · 2021Article
- Osteosarcoma Cell-Derived Small Extracellular Vesicles Enhance Osteoclastogenesis and Bone Resorption Through Transferring MicroRNA-19a-3p.Frontiers in oncology · 2021Article
- Downregulation of microRNA-605 indicates poor prognosis and promotes the progression of osteosarcoma.Oncology letters · 2020Article
- MiR362-3p Alleviates Osteosarcoma by Regulating the IL6ST/JAK2/STAT3 PathwayTechnology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is a malignant tumor derived from the skeletal system, often occurring in bone tissues, and it is the most common malignant tumor in the skeletal system, with more than 90% of cases being highly malignant. The present study was designed to explore the regulatory effects of microRNA (miR)-19a on the proliferation and apoptosis of osteosarcoma cells, and its influence on the activation of the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway. The expression of miR-19a in adult SaOS-2 osteosarcoma cells was downregulated via lentiviral transfection, and the cells were divided into a control group, NC-inhibitor group and miR-19a-inhibitor group. The expression of miR-19a in each group was detected via quantitative polymerase Chain reaction (qPCR). Next, the cell proliferation and apoptosis levels in each group were detected via methyl thiazolyl tetrazolium (MTT) assay and flow cytometry, respectively, and the level of reactive oxygen species (ROS) in cells was further determined. Moreover, the expression levels of apoptosis-related proteins and JAK2/STAT3 signaling pathway-related proteins were detected through western blotting. The expression level of miR-19a in the miR-19a-inhibitor group was significantly lower than that in the control group and NC-inhibitor group (P<0.01). Downregulation of miR-19a significantly reduced the proliferation ability (P<0.01), increased the apoptosis level of SaOS-2 cells (P<0.01), and significantly increased the ROS level in cells (P<0.01). Downregulation of miR-19a also promote cleaved caspase-3/caspase-3 expression in the OS cells (P<0.01) and inhibited Bcl-2/Bax expression (P<0.01). Additionally, downregulation of miR-19a markedly lowered the protein expression levels of phosphorylated (p-)JAK2, p-STAT3 and myeloid cell leukemia-1 (Mcl-1) in the cells (P<0.01). To conclude, downregulation of miR-19a can inhibit the JAK2/STAT3 signaling pathway in SaOS-2 cells, promote the expression of apoptosis-related proteins, and increase the ROS level in cells, thereby promoting apoptosis and inhibiting cell proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.